Molecular Templates, Inc. (MTEM)

NASDAQ: MTEM · IEX Real-Time Price · USD
0.473
0.00 (0.06%)
At close: Jun 2, 2023, 4:00 PM
0.470
-0.003 (-0.55%)
After-hours: Jun 2, 2023, 5:39 PM EDT
0.06%
Market Cap 26.63M
Revenue (ttm) 47.90M
Net Income (ttm) -60.26M
Shares Out 56.35M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 114,138
Open 0.470
Previous Close 0.472
Day's Range 0.460 - 0.488
52-Week Range 0.310 - 1.230
Beta 1.38
Analysts Hold
Price Target 1.25 (+164.49%)
Earnings Date May 15, 2023

About MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and M... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Eric E. Poma Ph.D.
Employees 111
Stock Exchange NASDAQ
Ticker Symbol MTEM
Full Company Profile

Financial Performance

In 2022, MTEM's revenue was $19.75 million, a decrease of -48.95% compared to the previous year's $38.70 million. Losses were -$92.72 million, 11.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for MTEM stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 164.49% from the latest price.

Price Target
$1.25
(164.49% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 day ago - GlobeNewsWire

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

1 week ago - GlobeNewsWire

Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration

2 weeks ago - GlobeNewsWire
}

Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohorts Partial hold based on previously disclosed cardiac events at 50 mcg/kg co...

2 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS collaboration, and related workforce reduction Announc...

2 months ago - GlobeNewsWire

Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

3 months ago - GlobeNewsWire

Molecular Templates Announces Participation in Upcoming Conferences

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

3 months ago - GlobeNewsWire

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

6 months ago - GlobeNewsWire
}

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

6 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

7 months ago - GlobeNewsWire

Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

7 months ago - GlobeNewsWire

Molecular Templates Announces Participation in Four Upcoming Conferences

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and deve...

9 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results

AUSTIN, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

10 months ago - GlobeNewsWire
}

Molecular Templates to Present at Upcoming Investor Conferences

AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

1 year ago - GlobeNewsWire

Molecular Templates' Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach

Presentations from multiple pipeline programs feature clinical and preclinical data demonstrating the unique biology of Molecular Templates' technology Presentations from multiple pipeline programs fe...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results

AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and de...

1 year ago - GlobeNewsWire

Molecular Templates to Present at the Upcoming Investor Conferences

AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results

AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and dev...

1 year ago - GlobeNewsWire

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

2 years ago - GlobeNewsWire

Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

2 years ago - GlobeNewsWire

Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I

Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a ...

2 years ago - GlobeNewsWire

Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of nex...

2 years ago - Benzinga